top of page

How Cambridge Innovation Capital has become a preeminent investment firm in Cambridge life sciences, and also a significant attractor of outside capital to Cambridge

May 6, 2024

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for those who are interested in investing in Cambridge innovation.

Recent Posts

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page